References
W.P. Harris, E.A. Mostaghel, P.S. Nelson, B. Montgomery, Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 6(2), 76–85 (2009)
T. Karantanos, C.P. Evans, B. Tombal, T.C. Thompson, R. Montironi, W.B. Isaacs, Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67(3), 470–479 (2015)
H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, J.S. de Bono, AFFIRM Investigators, Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012)
J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr, F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher, COU-AA-301 Investigators, Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995–2005 (2011)
K. Fizazi, H.I. Scher, A. Molina, C.J. Logothetis, K.N. Chi, R.J. Jones, J.N. Staffurth, S. North, N.J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O.B. Goodman Jr, C.N. Sternberg, J.H. Li, T. Kheoh, C.M. Haqq, J.S. de Bono, COU-AA-301 Investigators, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13(10), 983–992 (2012)
C.J. Ryan, M.R. Smith, J.S. de Bono, A. Molina, C.J. Logothetis, P. de Souza, K. Fizazi, P. Mainwaring, J.M. Piulats, S. Ng, J. Carles, P.F. Mulders, E. Basch, E.J. Small, F. Saad, D. Schrijvers, H. Van Poppel, S.D. Mukherjee, H. Suttmann, W.R. Gerritsen, T.W. Flaig, D.J. George, E.Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C.S. Higano, M.E. Taplin, Y. Park, T. Kheoh, T. Griffin, H.I. Scher, D.E. Rathkopf, COU-AA-302 Investigators, abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138–148 (2013)
D.E. Rathkopf, M.R. Smith, J.S. de Bono, C.J. Logothetis, N.D. Shore, P. de Souza, K. Fizazi, P.F. Mulders, P. Mainwaring, J.D. Hainsworth, T.M. Beer, S. North, Y. Fradet, H. Van Poppel, J. Carles, T.W. Flaig, E. Efstathiou, E.Y. Yu, C.S. Higano, M.E. Taplin, T.W. Griffin, M.B. Todd, M.K. Yu, Y.C. Park, T. Kheoh, E.J. Small, H.I. Scher, A. Molina, C.J. Ryan, F. Saad, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. 66(5), 815–825 (2014)
I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, S. Oudard, C. Théodore, N.D. James, I. Turesson, M.A. Rosenthal, M.A. Eisenberger, TAX 327 Investigators, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004)
D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, I.F. Tannock, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242–245 (2008)
D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr, J.A. Jones, M.E. Taplin, P.A. Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, E.D. Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004)
J.S. de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, I. Kocak, G. Gravis, I. Bodrogi, M.J. Mackenzie, L. Shen, M. Roessner, S. Gupta, A.O. Sartor, TROPIC Investigators, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after Docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010)
M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253–265 (2004)
M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, B.P. Levy, D. Escuin, X.K. Zhou, A. Gjyrezi, C. Chanel-Vos, R. Shen, S.T. Tagawa, N.H. Bander, D.M. Nanus, P. Giannakakou, Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71(18), 6019–6029 (2011)
E. Basch, D.A. Loblaw, T.K. Oliver, M. Carducci, R.C. Chen, J.N. Frame, K. Garrels, S. Hotte, M.W. Kattan, D. Raghavan, F. Saad, M.E. Taplin, C. Walker-Dilks, J. Williams, E. Winquist, C.L. Bennett, T. Wootton, R.B. Rumble, S.B. Dusetzina, K.S. Virgo, Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J. Clin. Oncol. 32(30), 3436–3448 (2014)
C.D. Taylor, P. Elson, D.L. Trump, Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol. 11(11), 2167–2172 (1993)
C. Sweeney, Y.-H. Chen, M.A. Carducci, G. Liu, D. Frasier Jarrard, M.A. Eisenberger, N.-N. Wong, N.M. Hahn, M. Kohli, N.J. Vogelzang, M.M. Cooney, R. Dreicer, J. Picus, D.H. Shevrin, M. Hussain, J.A. Garcia, R.S. DiPaola, Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial, in ASCO Annual Meeting. Abstract LBA2. Presented 1 June, 2014
N.D. James, Adding chemotherapy to initial therapy improves survival in patients with advanced, hormone-naïve prostate cancer, in ASCO 2015. Abstract 5001. (STAMPEDE trial)
F. Valcamonico, L. Ferrari, F. Consoli, V. Amoroso, A. Berruti, Testosterone serum levels and prostate cancer prognosis: the double face of Janus. Future Oncol. 10(7), 1113–1115 (2014)
P. Thelen, E. Heinrich, F. Bremmer, L. Trojan, A. Strauss, Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. Prostate 73(15), 1699–1709 (2013)
M.T. Schweizer, E.S. Antonarakis, H. Wang, A.S. Ajiboye, A. Spitz, H. Cao, J. Luo, M.C. Haffner, S. Yegnasubramanian, M.A. Carducci, M.A. Eisenberger, J.T. Isaacs, S.R. Denmeade, Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci. Transl. Med. 7(269), 269ra2 (2015)
Acknowledgments
The study was supported in part by donations of “gli Amici di Carlo” in memory of Carlo Ridon and “gli Amici di Andrea” in memory of Andrea Gadeschi.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Alfredo Berruti received honoraria for speech, Advisory Board, and research grants from Astellas, Janssen, and Sanofi. Alessandra Mosca received honoraria for speech from Astellas and Sanofi.
Rights and permissions
About this article
Cite this article
Bedussi, F., Valcamonico, F., Mosca, A. et al. Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients. Endocrine 54, 830–833 (2016). https://doi.org/10.1007/s12020-015-0827-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0827-z